Merck KGaA licenses US rights to tesamorelin from Theratech
EMD Serono, a US subsidiary of Germany's Merck KGaA, has exclusively licensed Theratechnologies' tesamorelin treatment for excess abdominal fat in HIV patients with lipodystrophy in the USA. Under the terms of the agreement, Theratech will retain rights to the drug in the rest of the world and receive royalties and milestones, along with an upfront payment from Merck of $30.0 million, which includes an $8.0-million equity investment, providing Merck with a 3.6% stake in the firm. Theratech will conduct all R&D for any additional indications, but Merck retains the option to co-develop and commercialize or co-commercialize these in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze